HIV incidence, defined as the rate of new HIV infections ...
Establishing HIV-1 Recent Infection Surveillance Using a Rapid Test for Recent Infection among Persons Newly Diagnosed with HIV Infection in [Country]Project OverviewInvestigators Countries will add investigators. NOTE: The investigators should discuss CDC’s level of engagement. Countries should decide what level of information CDC investigators will have access to and an explicit statement should be included in the protocol. There are multiple options 1) CDC will have non-engaged roles: CDC staff will not have access to personal identifying information (PII) or interact with participants. 2) CDC will be engaged and have access to PII.1.2 Collaborating Institutions[Countries will add Collaborating Institutions]1.3 AcronymsAIDS Acquired Immunodeficiency SyndromeANCAntenatal clinicART Antiretroviral TherapyCDC US Centers for Disease Control and PreventionCGHCenter for Global HealthDBSDried blood spotDGHTDivision of Global HIV and TBEDTAEthylene-diamine-tetra-acetic acidEIAEnzyme immunoassayFRRFalse recent rateFSWFemale sex workersHIV Human Immunodeficiency VirusHQHeadquartersHTC HIV testing and counselingHTSHIV testing servicesIDIdentification numberILBInternational Laboratory BranchIPImplementing partnerIPVIntimate Partner ViolenceKP Key PopulationLAgLimiting AntigenLDMSLaboratory Data Management SystemsLIMS Laboratory Information Management SystemsMoH Ministry of HealthMSMMen who have sex with menPEPFAR President’s Emergency Plan for AIDS ReliefPOCPoint-of-carePWIDPersons who inject drugsQCQuality controlR/LTRecent or long termRITARecent infection testing algorithmRNARibonucleic acidRTRIRapid test for recent infectionSOPs Standard Operating ProceduresSTI Sexually Transmitted InfectionTOTTraining of trainersTRITests for Recent InfectionUNAIDSThe Joint United Nations Programme on HIV and AIDSVCT Voluntary Counselling and TestingVL Viral LoadWHOWorld Health Organization 1.4 Funding Source(s)[Countries will add funding source(s)]2.0 Background HIV EpidemicIn 2019, an estimated 38.0 million people were living with HIV, of whom an estimated 1.7 million people (including 150,000 children) acquired their infection within the year, and 1 million people had died from AIDS-related illnesses ADDIN EN.CITE <EndNote><Cite><Author>UNAIDS</Author><Year>2020</Year><RecNum>1</RecNum><DisplayText>[1]</DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="5aa5xer2kfz2xyee2t4x2x2g9a0299ttwarf" timestamp="0">1</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>UNAIDS, </author></authors></contributors><titles><title>UNAIDS Global HIV & AIDS - 2020 fact sheet.</title></titles><dates><year>2020</year></dates><pub-location>Geneva, Switzerland.</pub-location><urls><related-urls><url>;[1]. There has been significant progress over the past decade in the global health response to HIV/AIDS. Between 2010 and 2019, the annual number of new HIV infections declined by 23% ADDIN EN.CITE <EndNote><Cite><Author>UNAIDS</Author><Year>2020</Year><RecNum>1</RecNum><DisplayText>[1]</DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="5aa5xer2kfz2xyee2t4x2x2g9a0299ttwarf" timestamp="0">1</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>UNAIDS, </author></authors></contributors><titles><title>UNAIDS Global HIV & AIDS - 2020 fact sheet.</title></titles><dates><year>2020</year></dates><pub-location>Geneva, Switzerland.</pub-location><urls><related-urls><url>;[1].In December 2019, 25.4 million people were receiving antiretroviral therapy (ART), an increase from 23.1 million people in 2018 and 7.8 million in 2010 ADDIN EN.CITE <EndNote><Cite><Author>UNAIDS</Author><Year>2020</Year><RecNum>1</RecNum><DisplayText>[1]</DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="5aa5xer2kfz2xyee2t4x2x2g9a0299ttwarf" timestamp="0">1</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>UNAIDS, </author></authors></contributors><titles><title>UNAIDS Global HIV & AIDS - 2020 fact sheet.</title></titles><dates><year>2020</year></dates><pub-location>Geneva, Switzerland.</pub-location><urls><related-urls><url>;[1]. In 2019, ART coverage was approximately 67% for all people living with HIV (68% for adults and 53% for children) ADDIN EN.CITE <EndNote><Cite><Author>UNAIDS</Author><Year>2020</Year><RecNum>1</RecNum><DisplayText>[1]</DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="5aa5xer2kfz2xyee2t4x2x2g9a0299ttwarf" timestamp="0">1</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>UNAIDS, </author></authors></contributors><titles><title>UNAIDS Global HIV & AIDS - 2020 fact sheet.</title></titles><dates><year>2020</year></dates><pub-location>Geneva, Switzerland.</pub-location><urls><related-urls><url>;[1]. Since the advent of widespread availability of ART, treatment of HIV infection has helped to change survival trends. AIDS-related deaths have fallen by 45% from 1.7 million people in 2005 to 690,000 million in 2019 ADDIN EN.CITE <EndNote><Cite><Author>UNAIDS</Author><Year>2020</Year><RecNum>1</RecNum><DisplayText>[1]</DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="5aa5xer2kfz2xyee2t4x2x2g9a0299ttwarf" timestamp="0">1</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>UNAIDS, </author></authors></contributors><titles><title>UNAIDS Global HIV & AIDS - 2020 fact sheet.</title></titles><dates><year>2020</year></dates><pub-location>Geneva, Switzerland.</pub-location><urls><related-urls><url>;[1]. In addition, through prevention of mother-to-child transmission programs, the world has seen enormous progress in reductions of new infections among children, where the number has fallen by 52% from 310,000 in 2010 to 150,000 in 2019 ADDIN EN.CITE <EndNote><Cite><Author>UNAIDS</Author><Year>2020</Year><RecNum>1</RecNum><DisplayText>[1]</DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="5aa5xer2kfz2xyee2t4x2x2g9a0299ttwarf" timestamp="0">1</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>UNAIDS, </author></authors></contributors><titles><title>UNAIDS Global HIV & AIDS - 2020 fact sheet.</title></titles><dates><year>2020</year></dates><pub-location>Geneva, Switzerland.</pub-location><urls><related-urls><url>;[1]. To accelerate the impact of the public health response to the HIV epidemic, in 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) issued ambitious fast-track treatment targets in an effort to eliminate HIV disease by 2030 ADDIN EN.CITE <EndNote><Cite><Author>UNAIDS</Author><Year>2016</Year><RecNum>3</RecNum><DisplayText>[2]</DisplayText><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="5aa5xer2kfz2xyee2t4x2x2g9a0299ttwarf" timestamp="0">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>UNAIDS</author></authors></contributors><titles><title>Ending the AIDS epidemic 2030 - Global Statistics 2016</title><secondary-title>UNAIDS Fact Sheet 2016</secondary-title></titles><dates><year>2016</year></dates><urls><related-urls><url>;[2]. The targets called for 90% of HIV-positive persons to be diagnosed, 90% of these to be on treatment, and 90% of these to have viral suppression by 2020 (’90-90-90’). Since then, countries have demonstrated strong political will towards meeting these targets by integrating UNAIDS’ 90-90-90 targets into their strategic plans through expanded testing strategies and adoption of “Test and Start” initiatives. As countries move closer towards reaching “90-90-90,” the real-time monitoring of the epidemiology of recent HIV infections will allow countries to adjust the public health response to sub-populations and locations where high levels of transmission may be occurring. Laboratory Tests for HIV-1 Recent Infection Antibody-based tests for recent infection (TRI) that can help distinguish recent from long-term HIV infection have been used since the mid-1990s to estimate population-level HIV incidence and to evaluate the impact of large-scale HIV interventions in preventing HIV infection PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ccm9va21leWVyPC9BdXRob3I+PFllYXI+MTk5NTwvWWVh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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ccm9va21leWVyPC9BdXRob3I+PFllYXI+MTk5NTwvWWVh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ADDIN EN.CITE.DATA [3, 4]. Interpretation of these assays is challenged, however, by a number of factors that can cause ‘false-recent’ results on the assay, including variable immune responses at the individual-level, performance of the assay across diverse HIV-1 subtypes and across populations with naturally low viral loads, current ART use, and advanced HIV disease. Improvements in the accuracy and interpretation of these assays have been made through use of multi-subtype antigens, robust biomarkers, the development of innovative testing formats and recent infection testing algorithms (RITAs) that incorporate the TRI result with other markers of chronic infection (e.g., viral load, evidence of treatment) PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LYXNzYW5qZWU8L0F1dGhvcj48WWVhcj4yMDE2PC9ZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LYXNzYW5qZWU8L0F1dGhvcj48WWVhcj4yMDE2PC9ZZWFy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ADDIN EN.CITE.DATA [5]. Testing for recent infection among newly diagnosed HIV-positive persons has been integrated into routine HIV surveillance in the United Kingdom and other European countries PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BZ2hhaXp1PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48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 EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BZ2hhaXp1PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48
UmVjTnVtPjc8L1JlY051bT48RGlzcGxheVRleHQ+WzZdPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxy
ZWMtbnVtYmVyPjc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlk
PSI1YWE1eGVyMmtmejJ4eWVlMnQ0eDJ4Mmc5YTAyOTl0dHdhcmYiIHRpbWVzdGFtcD0iMCI+Nzwv
a2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9y
ZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+QWdoYWl6dSwgQS48L2F1dGhv
cj48YXV0aG9yPk11cnBoeSwgRy48L2F1dGhvcj48YXV0aG9yPlRvc3N3aWxsLCBKLjwvYXV0aG9y
PjxhdXRob3I+RGVBbmdlbGlzLCBELjwvYXV0aG9yPjxhdXRob3I+Q2hhcmxldHQsIEEuPC9hdXRo
b3I+PGF1dGhvcj5HaWxsLCBPLiBOLjwvYXV0aG9yPjxhdXRob3I+V2FyZCwgSC48L2F1dGhvcj48
YXV0aG9yPkxhdHRpbW9yZSwgUy48L2F1dGhvcj48YXV0aG9yPlNpbW1vbnMsIFIuPC9hdXRob3I+
PGF1dGhvcj5EZWxwZWNoLCBWLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0
aC1hZGRyZXNzPkhJViBhbmQgU1RJIERlcGFydG1lbnQsIENlbnRyZSBmb3IgSW5mZWN0aW91cyBE
aXNlYXNlIFN1cnZlaWxsYW5jZSBhbmQgQ29udHJvbCwgUHVibGljIEhlYWx0aCBFbmdsYW5kLCBD
b2xpbmRhbGUsIExvbmRvbiwgVW5pdGVkIEtpbmdkb20uPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48
dGl0bGU+UmVjZW50IGluZmVjdGlvbiB0ZXN0aW5nIGFsZ29yaXRobSAoUklUQSkgYXBwbGllZCB0
byBuZXcgSElWIGRpYWdub3NlcyBpbiBFbmdsYW5kLCBXYWxlcyBhbmQgTm9ydGhlcm4gSXJlbGFu
ZCwgMjAwOSB0byAyMDExPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkV1cm8gU3VydmVpbGw8L3Nl
Y29uZGFyeS10aXRsZT48L3RpdGxlcz48dm9sdW1lPjE5PC92b2x1bWU+PG51bWJlcj4yPC9udW1i
ZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1bHQ8
L2tleXdvcmQ+PGtleXdvcmQ+QWdlIERpc3RyaWJ1dGlvbjwva2V5d29yZD48a2V5d29yZD4qQWxn
b3JpdGhtczwva2V5d29yZD48a2V5d29yZD5DRDQgTHltcGhvY3l0ZSBDb3VudDwva2V5d29yZD48
a2V5d29yZD5Db250YWN0IFRyYWNpbmcvKm1ldGhvZHM8L2tleXdvcmQ+PGtleXdvcmQ+RW5nbGFu
ZC9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RXBpZGVtaW9sb2dpY2FsIE1vbml0b3Jp
bmc8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkhJViBJbmZlY3Rp
b25zLypkaWFnbm9zaXMvZXBpZGVtaW9sb2d5Lyp0cmFuc21pc3Npb248L2tleXdvcmQ+PGtleXdv
cmQ+SGV0ZXJvc2V4dWFsaXR5L3N0YXRpc3RpY3MgJmFtcDsgbnVtZXJpY2FsIGRhdGE8L2tleXdv
cmQ+PGtleXdvcmQ+SG9tb3NleHVhbGl0eSwgTWFsZS9zdGF0aXN0aWNzICZhbXA7IG51bWVyaWNh
bCBkYXRhPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9r
ZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk5vcnRoZXJuIEly
ZWxhbmQvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk9kZHMgUmF0aW88L2tleXdvcmQ+
PGtleXdvcmQ+UG9wdWxhdGlvbiBTdXJ2ZWlsbGFuY2U8L2tleXdvcmQ+PGtleXdvcmQ+U2V4IERp
c3RyaWJ1dGlvbjwva2V5d29yZD48a2V5d29yZD5XYWxlcy9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+
PGtleXdvcmQ+WW91bmcgQWR1bHQ8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAx
NDwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbiAxNjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVz
Pjxpc2JuPjE1NjAtNzkxNyAoRWxlY3Ryb25pYykmI3hEOzEwMjUtNDk2WCAoTGlua2luZyk8L2lz
Ym4+PGFjY2Vzc2lvbi1udW0+MjQ0NTcwMDY8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQt
dXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI0NDU3MDA2PC91
cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+
ADDIN EN.CITE.DATA [6]. In these settings, the TRI assay has been used on blood collected from persons newly diagnosed with HIV infection. Because the tests are done centrally, test results are not available to providers immediately and cannot be used to identify persons most likely to transmit the virus. Alternative methods that can expedite the results of recent infection testing through point-of-care (POC) testing are needed. Rapid Test for HIV-1 Recent InfectionModified rapid test developed specifically to detect HIV-1 recent infection has been described in the literature PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HcmFuYWRlPC9BdXRob3I+PFllYXI+MjAxMzwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HcmFuYWRlPC9BdXRob3I+PFllYXI+MjAxMzwvWWVhcj48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ADDIN EN.CITE.DATA [7-9]. Similar to other tests for recent HIV infection, the rapid test for recent infection (RTRI) can improve our understanding of the HIV epidemic by demonstrating shifting dynamics in the HIV epidemic over time, such as changes in the proportion of recent infections allowing public health officials and providers to trace active HIV transmission networks PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OaWtvbG9wb3Vsb3M8L0F1dGhvcj48WWVhcj4yMDE2PC9Z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==
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OaWtvbG9wb3Vsb3M8L0F1dGhvcj48WWVhcj4yMDE2PC9Z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==
ADDIN EN.CITE.DATA [10] and target prevention strategies. While results from laboratory-based recent infection tests may take weeks to months to provide results due to sample transport, laboratory processing, and turnaround time from the testing laboratory to the referring clinic, the results of the rapid test for recent infection can be available within minutes, facilitating more efficient and targeted responses for maximum public health impact. A rapid assay using a single test device that can simultaneously diagnose HIV infection and differentiate between recent and long-term HIV-1 infection has been developed and described previously by CDC ADDIN EN.CITE <EndNote><Cite><Author>Granade</Author><Year>2013</Year><RecNum>8</RecNum><DisplayText>[7]</DisplayText><record><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="5aa5xer2kfz2xyee2t4x2x2g9a0299ttwarf" timestamp="0">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Granade, T. C.</author><author>Nguyen, S.</author><author>Kuehl, D. S.</author><author>Parekh, B. S.</author></authors></contributors><auth-address>Division of HIV/AIDS, National Center for HIV, Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA. tgranade@</auth-address><titles><title>Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device</title><secondary-title>AIDS Res Hum Retroviruses</secondary-title></titles><pages>61-7</pages><volume>29</volume><number>1</number><keywords><keyword>AIDS Serodiagnosis/*methods</keyword><keyword>HIV Antibodies/blood/immunology</keyword><keyword>HIV Envelope Protein gp41/blood/immunology</keyword><keyword>HIV Infections/*diagnosis/epidemiology/immunology</keyword><keyword>HIV Seropositivity/diagnosis/immunology</keyword><keyword>HIV-1/*immunology</keyword><keyword>Humans</keyword><keyword>Immunoenzyme Techniques</keyword><keyword>Incidence</keyword><keyword>Prevalence</keyword><keyword>Sensitivity and Specificity</keyword></keywords><dates><year>2013</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1931-8405 (Electronic)
0889-2229 (Linking)</isbn><accession-num>23281586</accession-num><urls><related-urls><url>;[7]. This technology was transferred to commercial partners, such as Sedia BioSciences (Portland, OR), for development of a commercial RTRI kit (i.e., Asante HIV-1 Rapid Recency Assay). The performance of the Asante Rapid Recency Assay has been evaluated using a well-characterized panel of cross-sectional specimens with known HIV serology status and recent or long-term status based on comparative Limiting Antigen (LAg) Avidity Enzyme immunoassay (EIA) results, which has been validated to detect recent infections PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EdW9uZzwvQXV0aG9yPjxZZWFyPjIwMTU8L1llYXI+PFJl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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EdW9uZzwvQXV0aG9yPjxZZWFyPjIwMTU8L1llYXI+PFJl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ADDIN EN.CITE.DATA [11]. This CDC in-house evaluation of the rapid test for recent infection has provided preliminary data which showed a percent agreement of 93.2% and a Spearman’s Rho of 0.83 when compared to results from the LAg Avidity EIA [13]. The mean duration of recent infection detected by the RTRI was approximately 6 months (161 days; 95% CI 148-174) ADDIN EN.CITE <EndNote><Cite><Author>Parekh</Author><Year>2017</Year><RecNum>13</RecNum><DisplayText>[12]</DisplayText><record><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="5aa5xer2kfz2xyee2t4x2x2g9a0299ttwarf" timestamp="0">13</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Parekh, B. </author></authors></contributors><titles><title>Performance evaluation of Asante? Rapid Recency Assay for HIV diagnosis and detection of recent infection: potential for surveillance and prevention</title><secondary-title>IAS 2017 abstract number A-854-0164-05286</secondary-title></titles><dates><year>2017</year></dates><urls></urls></record></Cite></EndNote>[12]. However, due to variability of immune response among people the transition from recent to long-term infection can occur from 3 to 9 months or beyond ADDIN EN.CITE <EndNote><Cite><Author>Parekh</Author><Year>2017</Year><RecNum>13</RecNum><DisplayText>[12]</DisplayText><record><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="5aa5xer2kfz2xyee2t4x2x2g9a0299ttwarf" timestamp="0">13</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Parekh, B. </author></authors></contributors><titles><title>Performance evaluation of Asante? Rapid Recency Assay for HIV diagnosis and detection of recent infection: potential for surveillance and prevention</title><secondary-title>IAS 2017 abstract number A-854-0164-05286</secondary-title></titles><dates><year>2017</year></dates><urls></urls></record></Cite></EndNote>[12]. This represents bell-shaped distribution around the mean. Therefore, although mean duration is approximately 6 months, a recent result for an individual is interpreted as having likely acquired HIV infection within the last one year. Preliminary data from ongoing field validations of the RTRI in Vietnam and Malawi have shown similar results with a Spearman’s Rho of 0.75 in Vietnam and 0.74 in Malawi when compared to the LAg Avidity EIA [14]. Based on similar tests for recent infection (e.g., LAg-Avidity EIA), we expect that, on average, there is a one in ten chance that someone who tests recent on the RTRI may have been infected over a year ago. Misclassification can vary depending on multiple contextual factors, including ART coverage, duration of ART, and proportion of elite controllers. RTRI kits based on the same concepts are in development by additional manufacturers as part of the technology transfer from CDC and will likely be available after thorough validation in CDC. As of December 2020, RTRI (i.e., HIV recency tests) have not been pre-qualified by the World Health Organization or approved by the U.S. Food and Drug Administration (FDA) for clinical use and are being used primarily for surveillance.Recency testing when used in an algorithm with viral load testing, can increase positive predictive value (PPV) of recent infection detection by identifying clients who may be misclassified as recent by RTRI, but may have suppressed viral load (<1000 copies/mL) because of antiretroviral treatment (ART) or being elite controllers. Preliminary data from field validations of the rapid test for recent infection found that 20%-40% of persons who tested recent were virally suppressed (HIV-1 RNA <1,000 copies/mL). The majority of them were individuals who were diagnosed previously (e.g., those on ART) but did not report a prior diagnosis. Where feasible, efforts should be made to screen out those with prior diagnosis during pre-test counseling and identify potential false-recent cases through existing client-level data (e.g., previous HIV diagnosis or ART use) to minimize false-recent results. Using a recent infection test on truly new positives who never had exposure to ART, the false-recent rate should be closer to 1-2%. To minimize these false-recent cases, viral load testing should be incorporated into a recent infection testing algorithm (RITA) at sites with ready access to viral load testing or sample referral networks. When viral load testing is included as part of a recent infection testing algorithm, persons who test recent and have a viral load ≥1,000 copies/mL will be considered a RITA recent case.Note: When viral load testing is included in the recent infection testing algorithm:Specify whether (and when) viral load results will be returned to the clientSpecify whether viral load results will be added to the client’s medical recordProvide explanation of these procedures during informed consent and on the information sheetIf viral load results are not returned to the client or provider, state that they will be available upon request by the patient or health care provider by request, for one year from their testing date. Rapid tests for recent infection have paved the way for establishment of a HIV recent infection surveillance system that can be integrated into routine HIV testing services (HTS). Surveillance data from this system can be used to rapidly detect and characterize recent HIV infection among newly diagnosed PLHIV to inform a timely and targeted public health response. 3.0 Project JustificationThe aim of this project is to establish a HIV-1 recent infection surveillance system among persons newly diagnosed with HIV infection by integrating RTRI into routine HTS. Data from this project will provide information on the proportion of newly diagnosed HIV-positive individuals who test recent and characterize these individuals to inform HIV prevention interventions. If such a system exists in a country, these data can be included in sentinel event reporting on HIV cases. This project is a collaboration between [PEPFAR implementing agencies: e.g., US Centers for Disease Control and Prevention, US Agency for International Development (USAID), US Peace Corps, and/or US Department of Defense], country Ministry of Health, and [PEPFAR implementing partner(s)]. 3.1 Project GoalThe goal of this project is to use an RTRI among persons tested in routine HIV testing programs to provide continuous epidemiological data on person, place, and time of recently infected and newly diagnosed individuals to inform HIV prevention and control strategies.3.2 Project Objectives Primary Objectives:To determine the proportion of individuals with recent HIV infection, as evaluated by RTRI, among newly diagnosed HIV-positive persons in participating health facilities To determine the proportion of individuals with recent HIV infection, as evaluated by recent infection testing algorithm (RITA), among clients newly diagnosed as HIV-infected in participating health facilitiesTo monitor trends in the proportion testing recent on the RTRI and/or RITA: Among newly diagnosed PLHIV by select demographic and HIV risk variables Among proxy population at risk of HIV infection, calculated as the number of clients testing recent (RTRI or RITA) divided by the number of clients testing HIV negative plus clients testing recentTo identify geographic locations associated with testing recent on the RTRI and/or RITA to inform geographic prioritization of HIV prevention interventions Secondary Objectives:To assess the demographic, behavioral, and clinical profile of HIV-positive clients by their recency status To determine the number and proportion of misclassified recent cases (tested RTRI recent with viral load <1000 cp/ml) by select demographic characteristics4.0 Methods 4.1 General DesignNewly diagnosed HIV-positive persons in routine HTS settings will be asked to consent for additional RTRI testing. Those who are identified as previously diagnosed HIV-positive cases (whether on ART or not) during pre-test counseling will not be tested with RTRI. RTRI will be performed after completion of the national testing algorithm (or in parallel with the second test depending on country preference and situation) for the purpose of classifying HIV-positive cases as recent or LT. RTRI result will not have any bearing on HIV status of the client determined by the national HIV testing algorithm. Persons who test recent on the RTRI may be requested to provide an additional sample of blood for viral load testing as part of a recent infection testing algorithm. Results will be linked to information on demographics, behavior, and access to services.4.2 Study Population The study population will be persons ≥[##] years of age who are diagnosed as a new HIV-positive case in HTS programs (i.e., previously undiagnosed HIV case) who provide informed consent for their blood to be tested for recent HIV infection. This can include newly diagnosed individuals encountered in routine antenatal HIV testing, voluntary counselling, and testing (VCT), provider-initiated testing and counselling (PITC), and index testing programs.NOTE:?Generally, those <15 years of age should not be tested with RTRI. Most HIV-positive cases <15 years of age are likely to have been infected perinatally and not likely to be recently infected. They may be misclassified as recent due to being on ART. Some countries have aligned the age criterion for recency testing with the age of consent for HIV testing in country (e.g., age 13-14 years are eligible for RTRI).4.3 Sampling and Inclusion CriteriaPersons with a new diagnosis of HIV will be offered the rapid test for recent infection during HTS. Informed consent will be obtained after discussing information about the test, including accuracy of results, and the implications of the results. Patients will be informed that clinical management will not be different whether they consent to the rapid recency test or not OR after consenting whether the infection is recent or long-term. See further details on informed consent in text box below. After informed consent is provided, a blood sample (finger prick or venous blood) will be collected. Counselling messages that explain recent HIV infection and reinforce HIV prevention messages and partner testing for all HIV infected persons will be incorporated into the counselling session. To utilize the rapid test for recent infection to meet our objectives, we will recruit all persons with a new diagnosis of HIV in HTS.Inclusion criteriaNewly diagnosed HIV cases at HTS visitGiving voluntary informed consent for supplementary testing using test for recent infectionAged ≥15 yearsExclusion criteriaClients who opt out or do not consent to RTRI testClients with documented history of testing HIV positive Clients reporting ART use for HIV management at any point during the HTS visit Persons with advanced HIV disease, including diagnosis of AIDS or low CD4+ T cell counts (below 200 cells per ?L)4.4 Data and Specimen Collection ProceduresPersons with a new diagnosis of HIV identified through routine HIV testing according to national HIV testing algorithm will be asked for their consent to provide a finger prick sample of blood (or 5mL of venous blood in the event that a finger prick sample is not feasible) for rapid testing for recent infection (Appendix A. Written Informed Consent- if applicable). This sample will be applied directly to the rapid test for recent infection by a trained HTS provider. The results of the rapid test for recent infection are available by examining the testing strip, which has a control line, a positive verification line, and a long-term infection line. HTS providers will use the Test for Recent Infection Results Form (Appendix B) to record the qualitative values (e.g. a check mark for each line that was present) by clinic and client unique ID and interpret the results. NOTE: There may be several options for informed consent. In alignment with national scientific regulations, a waiver of documentation of consent (i.e., not obtaining client’s signature on a consent form) may be requested, and an information sheet or oral script to be read to the potential subject provided as an appendix. An IRB may waive the requirement for a signed consent form for some or all of the prospective participants in a study if one of the following applies: 1) Consent is the only link – The only record linking the participant to the research would be the consent document, and the principal risk would be potential harm resulting from a breach of confidentiality. Prospective participants must decide if they want documentation linking them with the research and their wish is to govern; or2) Minimal risk and common non-consent procedure are involved – The research presents no more than minimal risk or harm to participants and involves no procedures for which written consent is normally required outside of the research context.The information or script should: State that the study involves researchExplain the purposes of the research and the expected duration of the subject’s participationDescribe any foreseeable risk or discomforts to the subjectDescribe any benefits to subjects or to others that may reasonably be expected from the researchDisclose alternatives Additional considerations for implementation within routine HTS and HIV program services: Blood collection to test for recent infection may be introduced during group information sessions, as is done for HIV testing in some settings. Clients should be provided necessary information about the test for recent infection and be given time to think about participation or opting out of the activity.If RTRI and/or RITA results are returned, clients will be provided counselling messages based on the rapid test for recent infection results along with routine counselling for HIV diagnosis (Appendix C) and information on recent and long-term infection (Appendix D). Individuals who test recent on the rapid test for recent infection will be noted as having an RTRI recent infection and will be asked to provide an additional blood sample (venous or dried blood spot [DBS]) to improve accuracy of test for recent infection status through viral load testing at a laboratory. NOTE: If it is possible, blood collected for routine HIV testing procedures (e.g., verification testing or other routine blood work for clinical care) may be used for testing for recent infection. This can avoid collection of an additional blood sample or additional finger prick.The Information Sheet (Appendix D) may be a handout offered to clients and/or presented as an informational poster in the lobby of a clinic to explain the new testing. Indicate if participants will receive a copy of the consent form and/or a copy of the information sheet (e.g., participants will not be provided a copy of the consent form but will be provided an information sheet (Appendix D)).4.5 Testing MethodsRapid test for recent infection: Using a finger prick or venous blood sample, preliminary HIV recent infection will be assessed using a rapid test for recent infection (e.g., Asante rapid recency assay or similar CDC validated test) that helps to distinguish recent infection (occurring, on average, in the past 6 months and ranges up to 12 months) from long-term infection (occurring over 12 months ago). The rapid recency assay is formatted as a lateral flow device with three lines, representing a control line (C) a positive verification line (V) and a long-term line (LT) to distinguish recent from long-term infection in 20 minutes (Figure 1). Limiting antigen applied to the third line (LT) forms the basis for separation of recent (low-avidity antibodies) from long-term (high-avidity antibodies) infection. The test can be interpreted qualitatively by visual assessment of the presence or absence of the three lines. The presence of all three lines indicates long-term (>12 months) HIV infection, while the presence of C and V lines indicates RTRI recent infection (<12 months). The presence of only the control line (C) indicates the client’s recency status is inconclusive (i.e. recency status could not be determined).Because RTRI is not approved by the World Health Organization-Prequalification (WHO-PQ) or other regulatory agency, results of this test will not be used for HIV diagnosis. HIV diagnosis will be made based solely on national testing algorithm and only newly diagnosed HIV-positive clients will be tested by RTRI. HIV status does not change, whether the specimen is classified as recent or LT. Accordingly, RTRI result with only control line is considered “inconclusive” for the purpose of this protocol (not “non-reactive or negative”). Figure 1: Rapid Test for Recent Infection Illustration019685Long-term infection C V LTRecent infection Inconclusive 00Long-term infection C V LTRecent infection Inconclusive Viral load testing: Viral load testing data are not routinely available for persons who test recent on the rapid test for recent infection. Therefore, an additional DBS or 5 ml of venous blood sample will be requested for viral load testing in a laboratory to identify persons who are virally suppressed and may be misclassified as recent by the RTRI. HIV-1 RNA viral load will be measured using a viral load testing platform that has been validated for plasma and DBS, such as the Abbott m2000 platform or Roche COBAS? AmpliPrep/COBAS? TaqMan? HIV-1 Test kit or a similar system, according to manufacturer’s instructions. Handling, storage, and transportation will be conducted according to the national guidance and standard operating procedures (SOPs). Recent infection testing algorithm (RITA): RITA combines results of recent infection assay and viral load for final interpretation of recency status. Specimens that test recent on RTRI with a viral load result ≥1,000 copies/mL will be noted as a RITA recent infection result PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BZ2hhaXp1PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48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 EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BZ2hhaXp1PC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48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 EN.CITE.DATA [5, 6] (Figure 2). Figure 2: Interpretation of a Recent Infection Testing Algorithm (RITA) Using a Rapid Test for Recent Infection and Viral Load Testing*3023235136588500NOTE: It is possible that on rare occasions an HIV-positive specimen may not be classified as recent or LT by RTRI. Technically this is an RTRI non-reactive (‘negative”) result but for this protocol, we use the term inconclusive. The client’s HIV status is based on the national algorithm and an inconclusive result should not impact the client’s status. Those preparing new recency protocols may choose to include the language in Appendix E. Appendix E provides guidance on additional testing (e.g., Geenius testing) that can provide useful information about the client’s HIV status, RTRI performance, and potentially assist with efforts to improve national HIV testing algorithms.Countries with existing/approved protocol may submit an amendment to the approved protocol incorporating the language below explaining why this is deemed important.4.6 Return of ResultsEligible clients will be informed that the RTRI will be done to test for recent infection. Please note that the HIV RTRI is currently under evaluation, it is not pre-qualified by the World Health Organization, and results of this test do not affect clients’ HIV diagnosis or clinical care. Results of this test will be used for surveillance purposes. We are not routinely returning the results of recency testing to clients. The risks and benefits of returning recency test results to clients should be weighed to inform development of country-specific recommendations to return or not to return recency results to clients. NOTE: If test for recent infection results are not returned to clients, it is still necessary to obtain informed consent to test for recent infection, explain why results will not be returned, explain the broader benefit that will be gained from their results to understand population-level information on recent HIV infection, and consider returning alternative population-level information (e.g., aggregated surveillance results describing proportion testing recent from that HTS site or geographic area). An explanation for not returning results may note that test for recent infection results will not be included in the client’s medical record, will not alter standard of care for clients that accept the test for recent infection, and that the test results cannot currently be meaningfully interpreted at the individual client-level. Return of VL test resultsEligible clients will be informed that the rapid test for recent infection will be supplemented with a viral load test as part of a recent infection testing algorithm.Recognizing that an individual has a right to know test results about themselves, we typically return individual test results of approved HIV-related tests. We are not routinely returning the VL result from the algorithm for the following reasons (for example):VL is not routinely done at the time of diagnosisThe VL at the time of diagnosis will not affect clinical managementFor [##] (months/years), the viral load result from the RITA will remain linked to the individual. Should an individual request to receive his/her viral load result, he/she will be instructed to contact his/her clinician for more information, and the clinician will access the result via a standard operating procedure to be developed by the study team.NOTE: There may be settings where viral load testing is conducted as part of a recent infection testing algorithm, but the viral load result will not be routinely returned to the client or clinic. In these cases, explain reasons why viral load results will not be returned. Clients should be informed that the viral load result will not affect their clinical management but will remain linked to their record for a defined period of time. If they would like to receive these results, they may do so by contacting their clinician who will follow a standard operating procedure for accessing the results. Suggested language during informed consent and on the information sheet is provided below: As part of the recent infection testing algorithm a viral load test will be done. The result of a viral load test done as part of the recent infection testing algorithm is not considered clinically actionable under Ministry of Health HIV treatment guidelines at this time. However, if you are interested in receiving the result, please contact your clinician within [#] months.4.7 Data ManagementAll results from rapid tests for recent infection for newly diagnosed HIV-positive clients (Appendix B) and additional information collected from the cases including demographics and risk behavior will be entered electronically into an electronic data capture application that implements comprehensive managed authentication and authorization functions, and includes essential provisions for data quality assurance, data integrity, and information security by HTS staff assigned to the project. Automated data quality checks will be programmed into the electronic database to improve the validity of data entered, including checks in the completeness of responses, restrictions in the range of numerical data and responses for categorical data. Specimens that are sent for viral load testing at a central laboratory (i.e., those that test recent on the rapid test for recent infection) will be labelled with a client’s unique ID and HTS facility code. Once the specimens are received at the testing laboratory, they will receive a laboratory-generated specimen identification number and tested for viral load using routine procedures for testing and documentation of results. Once available, a print-out of viral load results labelled with the client’s unique ID, will be transmitted back to the HTS facility, viral load results will be entered into the electronic database, and test results will be updated. All paper-based forms will be stored in a locked cabinet at the HTS facility with access limited to key study staff according to the data security and storage procedures in place at the HTS site. Comprehensive data security measures will be implemented, including human, physical, and electronic procedures and protections at every stage of the activity: data collection, transfer, and storage. All paper-based registers/logbooks for RTRI will be kept in secure locations accessible only to authorized personnel.All electronic devices, if used, will be physically secured when not in use. All electronic devices and databases will be encrypted, password protected and accessible only by appropriate staff. The database will be backed up monthly on a secure, external system. All staff with access to data will receive training in data security and confidentiality and must individually affirm that they will abide by data security and confidentiality principles and procedures (Appendix F).The protocol authors will prepare a separate data management plan as an appendix to the protocol that provides sufficient detail on data security measures. Data GovernanceAll data collected through this protocol are the property of the country Ministry of Health and will be monitored by the investigators of this project. All investigators will have unimpeded access to the data. Data ArchivalAt the end of the project after the final report has been disseminated, the project data manager will transmit a copy of all data to a designee within the Ministry of Health and the investigators of this project.NOTE: The electronic data capture application will either 1) meet CDC’s minimum requirements for health information systems and data management for surveillance purposes (per Division of Global HIV and Tuberculosis [DGHT] data management checklist) or 2) is described in sufficient detail to allow an independent technical review by a data management subject matter expert. Protocol authors are advised to consult with health information systems and data management subject matter experts to ensure that the selected application will meet minimum requirements as per the DGHT data management checklist or equivalent. According to country context, provide additional information in the data management section to address the following:* Type of electronic data capture system and whether it is part of an existing health information systems; if not a part of existing health information system, consider interoperability with EMRs (e.g., OpenMRS)* How automated data checks will be performed to ensure data integrity, coherency, and consistency in the data collection and aggregation process* Whether any personally identifiable information will be collected* Sources of any additional data linked to test results (e.g., HTS register or module for demographics, behavior, and access to services)* Process to establish role-based access, permissions and privileges for database and/or health information system* Description of how electronic devices will be physically secured (i.e., locked file cabinet)* Process for securely storing information/data collected from the activity* Plans for archiving data* Special considerations if surveillance data is to be abstracted from a laboratory information system portal.Data Management Standard Operating Procedures will provide additional detail.4.8 Data AnalysisPrimary Analyses:Determine the proportion of individuals with recent HIV infection, as evaluated by RTRI, among people who present for HIV testing and test HIV-positive in participating health facilities Determine the proportion of individuals with recent HIV infection, as evaluated by recent infection testing algorithm (RITA), among people who present for HIV testing and test HIV-positive in participating health facilitiesMonitor trends in the proportion of people testing recent on the RTRI and/or RITA: Among people who present for HIV testing and test HIV-positive by select demographic and HIV risk variables, including age, sex, risk behavior, and access to health services (Appendix G)Among a proxy population at risk of HIV infection, calculated as the number of clients testing recent (RTRI or RITA) divided by the number of clients testing HIV negative plus clients testing recentIdentify geographic locations associated with testing recent on the RTRI and/or RITA to inform geographic prioritization of HIV prevention interventions using GIS software packages (e.g., ArcGIS, QGIS) and maps (e.g., dot maps, shaded maps, heat maps, bubble maps) to visualize recent and long-term HIV infections by location of health facility or client residenceSecondary Analyses:Assess the demographic, behavioral, and clinical profile of HIV-positive clients by their recency status Determine the number and proportion of misclassified recent cases (tested RTRI recent with viral load <1000 cp/ml) by select demographic characteristicsCalculate the number and proportion of eligible persons who choose not to participate in or decline testing for recent infection. Where possible, comparisons of demographic and behavioral characteristics of persons who did not receive testing for recent infection to those who were tested will be made. Further, more advanced statistical analyses may be conducted to identify demographic, behavioral, and health service-related factors associated with testing recent versus long-term on the RITA. Demographic and behavioral characteristics of persons with recent infection and long-term infection can be compared using a 2-sided Pearson chi-square or fisher exact test to assess for statistical significance. Continuous variables can be compared using the Wilcoxon rank sum test. Regression analysis can be conducted to identify independent factors associated with recent infection. Where appropriate, analyses will account for site clustering and/or include examination of differences across sites. NOTE: If client residence (e.g., village) is collected and used to map recent HIV infections, consider the lowest level geographic unit to protect client privacy and reduce the risk of re-identification of clients. If residence will be collected, describe how it will be collected.4.9 Training, Monitoring, and Quality ControlTraining, monitoring and quality control measures will be applied to ensure that the implementation of this project is done according to protocol with a high degree of quality, accuracy, completeness, and representativeness. Training, supervision, and quality control will include multiple components and actors. Sensitization meetings may be held with all stakeholders prior to implementation.TrainingTraining will be conducted starting with training of trainers (TOT) to develop a cadre of trained personnel who can then provide training to site-level personnel as well as help monitor quality of testing. Training for site-level personnel involved in this project will occur prior to its implementation in sites pre-selected by and could include nurses, midwives, doctors, and laboratory technicians. Training will cover the following areas with both didactic and hands-on practice where appropriate:Human subjects protectionThe objectives of project Eligibility criteriaThe completion of the project data collection formsInformed consent process and completion of the consent form The RTRI procedures with hands-on testing (3 quality control [QC] specimens + 10 specimens of training panels) The preparation, packaging and storage of blood specimens for viral load, including DBS, if not routinely doneThe secure and timely transport of specimensHuman and physical procedures and protections to ensure the security and confidentiality of data[IF APPLICABLE:] The return of results, including appropriate training on:Accurate and clear counseling messages on what ‘recent infection’ means and implications for disclosure of status to partnersAssessment of risk for intimate partner and gender-based violence Assessment of client’s psychological well-being pre- and post- recency testingReferral systems for individuals to receive psychosocial support as neededTraining for health facility implementersTraining for laboratoryTraining for data management and analysisTraining for data security, privacy and confidentialityThe training data will be logged in a standardized spreadsheet to document both competency in hands-on practice and knowledge using a set of questions. Only those meeting minimum passing criteria will be certified as competent testers. MonitoringMonitoring teams will provide regular oversight to HTS sites to verify procedures are being followed at the site level, including:Persons who do not consent to rapid testing for recent infection are not tested;The HTS site has an appropriate supply of laboratory consumables;Data forms are being completed appropriately;Specimens going to the laboratory are appropriately labeled with the client unique identification number, stored, and transmitted, within the timeframe prescribed by the protocol;The completion, handing and storage of data and biological specimens is in accordance with procedures and protections to ensure the security and confidentiality of data as described in the protocol; andAdverse events, including social harm.Project investigators with Ministry of Health (MoH) staff will hold monitoring and evaluation visits at least on a quarterly basis. A supervision checklist, such as SPI-RT/RTRI, will be used to assist supervisors in conducting supervision visits and documenting results of such visits. Sites where supervision visits document problems will be prioritized for corrective actions and follow-up supervision visits. Quality Assurance / Quality controlAll tests will be performed according to manufacturer’s instructions including the use of appropriate QC specimens, and all tests will be interpreted according to manufacturer’s instructions, unless stated otherwise. Quality assurance of activities will take place primarily at health facilities where rapid testing for recent infection will be conducted. Rapid test for recent infection kit verification will be carried out using QC panels at regular intervals, for example at the beginning of each month or upon receiving a new lot and a new consignment at the hub laboratory.All testers using the rapid test for recent infection will undergo hands-on training before testing client specimens, competency testing during their training, and proficiency testing thereafter annually. Intermittent supervision of the sites conducting recent infection testing will be carried out by trained staff and the investigators to ensure quality testing standards are maintained. The project data manager will review all paper data forms and the electronic database for incomplete or invalid data on a continual basis, with monthly summaries made available to investigators; Similarly, the hub and/or central laboratory will review all arriving specimens to ensure:Sample requisition forms are complete and correspond to associated specimensSpecimens arrive in a timely fashion Specimens are appropriately packagedSpecimens are in good conditionStandard sample rejection procedures/documentation in place in country will be used for this surveillance activity. Sites submitting specimens or forms that do not meet standards outlined in SOPs will be prioritized for supportive supervision. All HTS clinics will have accessible SOPs for the following procedures: Blood specimen collection by venipuncture using universal precautions and universal blood collection procedures (according to each HTS site SOP)Handling, storage, and transportation (according to the national algorithm and SOPs) HIV diagnosis using antibody detection assays (according to the national algorithm and SOPs) Rapid test for recent infection assay proceduresData flow [AS APPLICABLE] Returning of test result, including RTRI, RITA, and viral load test 5.0 Ethics The probability and magnitude of harm or discomfort anticipated with the integration of recent infection testing are currently not anticipated to be that much greater than those encountered during the receipt of routine HTS. In addition to routinely recorded clinical data and blood specimens, this activity will also collect an additional blood sample for rapid recent infection testing. Participants will be consented for the additional blood draw. All participants who give consent to receive rapid recent infection results, will be given the results with counseling. Clients will not benefit directly from participation, though the data collected by this project will be used to improve HIV prevention interventions and treatment service for the communities in which they live. The main risk of participating in this study is the breach of confidentiality, namely the disclosure of personal medical information collected as part of this activity, such as HIV status. However, project staff will implement human, physical and electronic procedures and protections to ensure the confidentiality and security of personal information. No names or personal identifiers will be used in reports, presentations, or publications from this project. To prevent inadvertent identification of study participants due to fine stratification (e.g., small cell size related to residence), any stratification units resulting in less than 25 participants will not be released. An additional risk is the breach of confidentiality and disclosure of personal medical information collected as part of this activity, such as HIV status. However, study staff will implement human, physical and electronic procedures and protections at every stage of the study to ensure the confidentiality and security of personal information.NOTE: Include the following text if opt to return RTRI resultsReturn of routine HTS test results will occur according to the standard clinic practice, however, given that recent infection testing is new to this setting, there may be some risk in informing participants whether they were recently infected with HIV. Like virtually all laboratory tests, recency testing is not 100% accurate and misclassification may occur. Recognizing the gravity of HIV diagnosis, a newly diagnosed patient with an understanding that that infection was contracted in the past year, may convey added psychological and emotional distress. This may include stresses related to determining the source of their infection, as well as that which impacts social and family structures. Additionally, it is not known whether there may be increased intimate partner violence (IPV) or other unanticipated adverse events associated with a client’s knowledge of recent infection and perceived source of infection based on the timing (i.e., a sex partner within the past year if test recent). Community consultationsThrough collaboration and community intelligence, community involvement adds value and enhances the expertise of technical staff, researchers, service providers and others involved in public health programs or research and serves as a critical piece that must be coupled with science to drive policy changes. As such, country programs must have a community engagement plan in place with HIV-infected and HIV-affected communities through routine community consultations on strategies for accelerating control of the HIV epidemic, such as HIV recency testing of newly diagnosed. Appendix H provides further detail around community consultations before, during, and after recent infection surveillance program implementation.Protection of participants <18 years of age Every measure possible will be taken by staff to minimize potential risks to the participants, including minors. In [country], minors who are at least [##] years of age can consent for HIV testing. Extra steps will be taken to ensure that persons below 18 years old receive the support needed to understand the activity, procedures for participation, and risks and benefits of participation. Protection of other vulnerable populationsThe volunteer that is likely to be vulnerable to coercion or undue influence might include individuals such as minors, pregnant women, soldiers, the physically handicapped, or mentally incompetent persons. Other vulnerable volunteers could include persons living on streets and very sick persons who are incapable of giving consent or providing continuing consent.Special considerations apply to participants under 18 years of age who state being or having been: 1-engaged in sex work (i.e., subject to sexual exploitation), 2-trafficked, or 3-subjected to violence per the CDC DGHT guidance for the Development of Surveillance, Research or Program Protocols that Include Children who are Sex Workers, Trafficked or Victims of Violence. Such participants will be referred for support services (intimate partner violence/ gender-based violence if available) in line with standard procedures at the testing site. Reporting of Adverse Events or Protocol ViolationsAdverse incidents, to include unexpected protocol violations, security incidents harming participants or surveillance staff, breaches of confidentiality, or adverse physical or mental reactions to surveillance procedures will be reported to all relevant ethical review committees. Health facility staff or surveillance staff will report the incident in writing or email to the project coordinator (for their facility or next in command) within 24 hours of discovering the event. The study coordinator will determine through team consultation whether an event took place, and if so, report to the study Principal Investigators and local civil society leadership within 24 hours and to ethical review committees within 5 to 10 days. The project coordinator will complete follow-up reporting of any additional information required.NOTE: If RTRI or RITA results will be returned to the client, we recommend including a description of how incidents and adverse events related to the return of results, including social harm or intimate partner violence, will be monitored and any protective measures to reduce the risk to clients or partners of clients. For example, social harm monitoring may involve: longitudinal follow up assessment of index clients and contacts, oral or written reporting by health facility staff and/or community-based health workers or volunteers, a telephone hotline, etc. Additionally, if transmission modes are being elucidated it will be important to discuss how priority/key populations will be protected.Any unanticipated problems involving new or increased risk to participants or others will be promptly reported to the investigators, MoH and IRB(s).6.0 Timeline[Countries will provide specific timelines based on their local objectives with respect to integration of the rapid test for recent infection into HTS.]7.0 Data Use and DisseminationAggregate surveillance data describing where and among whom recent infections are occurring among newly diagnosed PLHIV will be shared widely with in-country stakeholders on an ongoing basis, for example through the national data repository dashboards, to inform the national HIV response to guide public health response as well as prevention and control measures. Stakeholders will include government (Ministry of Health), civil society, health facilities, non-governmental organizations, donors, international technical experts. Periodic, formal dissemination of results will take several forms, including national epidemiologic reports or surveillance reports for distribution and peer-reviewed publications.NOTE: If RTRI or RITA results will be used at the site-level or individual-level (e.g., if used for index testing triage), it is necessary to describe this use and provide relevant information during informed consent process.For example: All index cases will be offered index testing/partner notification services as part of routine HTS. If there are more contacts of index cases than can be traced with existing personnel/resources, these results (RTRI result; RITA result; VL result) may be one of several criteria used to prioritize which index cases’ contacts are traced first. 8.0 References ADDIN EN.REFLIST 1.UNAIDS, UNAIDS Global HIV & AIDS - 2020 fact sheet. 2020: Geneva, Switzerland.2.UNAIDS, Ending the AIDS epidemic 2030 - Global Statistics 2016. UNAIDS Fact Sheet 2016, 2016.3.Brookmeyer, R. and T.C. Quinn, Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol, 1995. 141(2): p. 166-72.4.Janssen, R.S., et al., New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA, 1998. 280(1): p. 42-8.5.Kassanjee, R., et al., Viral load criteria and threshold optimization to improve HIV incidence assay characteristics. AIDS, 2016. 30(15): p. 2361-71.6.Aghaizu, A., et al., Recent infection testing algorithm (RITA) applied to new HIV diagnoses in England, Wales and Northern Ireland, 2009 to 2011. Euro Surveill, 2014. 19(2).7.Granade, T.C., et al., Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device. AIDS Res Hum Retroviruses, 2013. 29(1): p. 61-7.8.Girardi, S.B., et al., Evaluation of rapid tests for human immunodeficiency virus as a tool to detect recent seroconversion. Braz J Infect Dis, 2012. 16(5): p. 452-6.9.Soroka, S.D., et al., Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diagn Lab Immunol, 2005. 12(8): p. 918-21.10.Nikolopoulos, G.K., et al., A network intervention that locates and intervenes with recently HIV-infected persons: The Transmission Reduction Intervention Project (TRIP). Sci Rep, 2016. 6: p. 38100.11.Duong, Y.T., et al., Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS One, 2015. 10(2): p. e0114947.12.Parekh, B., Performance evaluation of Asante? Rapid Recency Assay for HIV diagnosis and detection of recent infection: potential for surveillance and prevention. IAS 2017 abstract number A-854-0164-05286, 2017.Appendix A. WRITTEN CONSENT Form FOR rapid TESTING for recent infection IN HTSFlesh-Kincaid Grade Level = 5.7This informed consent form is for persons who have a new HIV diagnosis. The informed consent form has two parts:Information Sheet (to share information about the program with you)Certificate of Consent (for signatures if you agree to take part)You may have a copy of the form.Part I. Information sheetPurpose of the Public Health Program activityMinistry of Health is doing a surveillance activity to know how many new HIV infections have happened in the past one year. We will use a new test called a “Recent Infection Test,” during the usual HIV tests. Participation in this activity is voluntary. Your choice to participate will not change your care. Individuals will be asked to participate if they are:At least [##] years old, Never diagnosed with HIV before,Never have taken HIV medication (ART) before, and HIV positive based on tests today. ProceduresIf you agree to take part, we will collect a few small drops of blood. We will use the blood to do the “HIV rapid test for recent infection.” I may ask you to take an additional blood sample (approximately 2 tablespoons). This blood will be used to measure the amount of virus in the blood (viral load). I will put a number on the container with the blood. Your name will not be on the container with your blood. This will keep your information private. Because the Recent Infection Test is currently under evaluation and not yet approved by the World Health Organization, the test result will not be available. Your HIV diagnosis and access to normal care will not change. Risks and Benefits:We do not think the recent infection test (or viral load test) will add to your risks. We may need to prick your finger again if we are unable to get enough blood with the finger pricks for HIV testing. You may feel some pain and soreness from the finger prick. This is similar to routine testing. There is always a risk your personal information may accidentally be shared to unauthorized persons. Every effort will be made to keep your information private. There is no direct benefit from participating. The results will help inform HIV services in your country. If you have questions about this activity or if you feel that you have been harmed by taking part, you may contact [INSERT CONTACT HERE]If you have any questions on what your rights are as a participant in this project, you can contact the Secretariat for the Ethical Review Committee [INSERT CONTACT HERE]PART II: Certificate of Consent/AssentI have read the previous information, or it has been read to me. I was able to ask questions about the program. My questions have been answered to my satisfaction. ? I consent/assent voluntarily to have my blood tested for recent infection. I understand this will not change my medical care.? I do not consent/assent voluntarily to have my blood tested for recent infection. I understand this will not change my medical care.Print Name of Participant_____________________________________________________Signature of Participant ______________________________________________________Signature Date ______________________________________________________________Print Name of person taking the consent/assent ____________________________________Signature _______________________________________________________________Signature Date ___________________________________________________________UPI created_____________________________________________________ If needed, due to language barrier, this consent/assent was witnessed by:Print Name of person witnessing the consent/assent ____________________________________Signature _______________________________________________________________Signature Date ________________________________________________________NOTE: If optional testing will be done to investigate RTRI inconclusive or discordant results (see appendix E), language should be added to the consent form to describe procedures and potential risks and benefits. Consider using the following language: ProceduresThe recent infection test also gives an HIV result. In rare cases, the HIV result on the recent infection test may differ from the national HIV testing algorithm. In this case, we may ask you to do additional tests. If you agree, this may include a repeat of the recent infection test, the national testing algorithm, and/or a third HIV test. This information will help the Ministry of Health improve the HIV program. Your HIV status will be determined by the national algorithm per standard practice. Risks and BenefitsWe may need to collect more blood using finger prick(s) or blood draw. You may feel some pain and soreness from the finger prick(s) and/or blood draw. There is no direct benefit from participating in the additional testing, but the results will help inform HIV services in the country.Appendix B. Example Rapid Test for Recent Infection Results Documentation FormHIV Testing ServicesRapid Test for Recent Infection?Sample Type (Circle): Finger Prick Venous Blood Plasma SerumTest Name: Kit Lot #Kit Expiration Date (DD/MM/YYYY)Site/Facility NameTester Name????NoFirst initialLast nameHTS IDARV IDDate of Diagnosis(DD/MM/YYYY)Site/Facility NameSample IDVisual Results(Mark "√" if Line is present)Recency Interpretation*(All 3 lines =LT; C&V Lines= Recent; Only C Line= Inconclusive)(Please circle one)Control LineVerification LineLong Term LineQC-Long term???LTRecentIncInvalidQC – Recent???LTRecentIncInvalidQC-Inconclusive???LTRecentIncInvalid1?????LTRecentIncInvalid2?????LTRecentIncInvalid3?????LTRecentIncInvalid4?????LTRecentIncInvalid5?????LTRecentIncInvalid6?????LTRecentIncInvalid7?????LTRecentIncInvalid8?????LTRecentIncInvalid9?????LTRecentIncInvalid10?????LTRecentIncInvalid11?????LTRecentIncInvalid12?????LTRecentIncInvalid13?????LTRecentIncInvalid14?????LTRecentIncInvalid15?????LTRecentIncInvalidResults Reviewed on:Results Reviewed By:*RTRI negative results are considered inconclusive (inc) for the purpose of classification. They are not to be used for diagnosis of HIV infection which should be done solely based on national testing algorithm.Appendix C. Counseling Procedures and Messages for Return of Test Results (if applicable)StepMessage1Ask client whether he/she has any questions about his/her care, specifically the new HIV diagnosis and treatment. Ask whether he/she has any questions regarding test for recent infection and if ready to receive test for recent infection results.2Provide test for recent infection result and allow time to process. The nurse/counsellor should anticipate the emotional reaction from a client who has been told they were recently infected and its implications. A client may express anger, shock, confusion, distrust, etc. Use counselling skills: listen to client and support accordingly.2.1If tested long-term on the rapid test for recent infection state the following:We tested your blood sample and the test indicates you may have long-term infection. You were most likely infected with HIV more than 12 months ago and possibly several years ago. The test cannot tell exactly when you were infected or who infected you. There is a small chance that the result is not correct and that you have been infected within the past 12 months.Take your time; we have plenty of time to talk about your results.How do you understand this result?How are you feeling about this result??How can I help support you?2.2If RITA recent (test for recent infection + viral load test) state the following: We tested your blood sample and the tests indicate you may have recent infection. You were likely infected with HIV within the past 12 months. The test cannot tell exactly when you were infected or who infected you. There is a small (one in ten) chance that the result is not correct and that you have been infected for more than 12 months and possibly for several years. Take your time; we have plenty of time to talk about your results.How do you understand this result?How are you feeling about this result??How can I help support you?3Answer any questions the client may have about test for recent infection test result.4Discuss and reinforce HIV prevention messages and partner testing for all HIV infected persons:Your result does not reflect your partner(s) HIV status. You need to ask your partner(s) to get tested whether you tested as having a recent infection or a long-term infection. We have many options on how to do so and we can discuss further. You do not need to tell your partners the results from your test for recent infection, the important thing is to share your HIV status and that you are on treatment.You can pass HIV on to your loved one(s) by having unprotected sex. Disclosing your HIV status to your loved ones may help you discuss ways that you can use to protect them from HIV.A good practice to prevent transmission to unborn or newborn children and partner(s) is to be on treatment, and with partner(s) using a condom during sex The best way to keep yourself healthy and to keep your partner(s) healthy is to start taking ART. Once you start HIV treatment, it is critical that you continue taking it every day as prescribed by your nurse or doctor. ?Appendix D. Information Sheet on Understanding Recent and Long-term HIV Infection (if applicable – returning results)Flesh-Kincaid grade level: 6.1What does recent HIV infection mean? Recent HIV infection means a person likely got HIV within the past one year. People with recent HIV infection have high amounts of HIV in their blood. Having more virus means that it is easier to pass on infection to others. HIV medications (antiretrovirals or ARVs) lower the amount of HIV in your body. ARVs help you to stay healthy. ARVs make it less likely for you to pass the infection to others, including unborn and breastfeeding infants and sex partners. ARVs need to be taken every day or as prescribed by a doctor for your health. This will also lower the risk of passing HIV. Now, the test for recent infection is a research tool. There is a small (one in ten) chance that someone who got HIV more than one year ago will test as if they have a recent infection. The test cannot tell exactly when you got HIV. The test cannot tell you who passed the infection to you.What does long-term HIV infection mean? A long-term HIV infection means a person likely got HIV more than one year ago. A person with long-term HIV infection can still pass HIV to other people. People with any HIV infection should start and stay on HIV medications (ARVs) as prescribed by your doctor for your health. ARVs lower the risk of passing HIV to others. At this time, the test for recent infection is a research tool. There is a chance that someone who got HIV within the past one year will test as if they have a long-term infection. The test cannot tell exactly when you got HIV. The test cannot tell you who passed the infection to you.How can I reduce the risk of transmitting HIV to others?If you have a recent or long-term HIV infection, you have HIV in your blood. Start HIV medication (ARVs) as soon as possible. Take the pills everyday as prescribed by your healthcare provider. If you forget to take your HIV medicine, take it as soon as you remember. If HIV medications make you feel sick, talk to your healthcare provider.You can pass HIV to sex partners [and to your unborn or breastfeeding baby or persons you share needles with]. Not having sex is the best way to not pass HIV to your sex partner. If you do have sex, you and your partner need to use a condom the right way every time you have sex. Limit the number of people you have any kind of sex with. If you have HIV and are pregnant or breastfeeding, it is important to start and stay on HIV medications. It is important for your baby to take HIV medicines for 6-12 weeks after birth. This will lower the chance of passing infection on to your baby. If you inject drugs outside of the clinic or hospital, only use sterile needles or syringes. Do not share the needle or syringe with anyone else.Appendix E. Handling of RTRI Inconclusive or Discordant Results (optional)RTRI is intended to help determine the recency status of people newly diagnosed HIV-positive. The test has not yet been approved by WHO-PQ or other regulatory body for the diagnosis of HIV-infection. Therefore, the RTRI result should not have an impact on HIV diagnosis. Currently the test is used either 1) after completion of the national testing algorithm, or 2) concurrently with second test (T2) to determine the status of new HIV-positive cases as a recent infection (<12 months) or a long-term infection (>12 months). In rare cases, where RTRI may show a discordant result with the national testing algorithm, HIV diagnosis should be provided based on the national testing algorithm result. However, it may be useful to investigate these rare cases, if feasible, as part of the recency research protocol. This will require additional testing. Guidance is provided below to identify potential testing errors and to determine the true HIV status of these rare cases. Defining the status of these cases will improve our understanding of RTRI performance and may help improve national testing algorithms in the future.RTRI inconclusive is defined here as valid RTRI tests that do not provide HIV recency status as recent or long-term. Technically, from the laboratory perspective, they are RTRI negative cases with no verification line (V) or long-term line (LT). Invalid tests are not considered here as part of inconclusive results.Scenario 1: It is expected that almost all HIV-positive cases will be classified as recent or long-term. However, there may be rare cases where the RTRI yields an inconclusive result. As a first step, specimens with an inconclusive result will be retested with RTRI (Flow chart 1) to eliminate testing error. This can be done immediately if the client is available at the testing site. Alternatively, if recency testing is conducted at regional or district labs, retesting can occur using leftover specimen. If retesting gives recent or long-term result instead of inconclusive, this can be used. If the result is still RTRI inconclusive, the national testing algorithm will be repeated to confirm HIV-positive status of the client. If recency testing is performed at the time of retesting for verification, then there is no need to repeat national testing algorithm. If the results of testing by the national algorithm and RTRI remain discordant, the next step will be to test using the Geenius HIV-1/2 assay (BioRad Laboratories). For the purpose of this protocol for aggregate data analysis only, final HIV status will be based on the Geenius result. This will not affect the HIV status of the client, which is based on national testing algorithm. Flow chart 1. Stepwise process to resolve RTRI inconclusive (i.e. RTRI negative) cases. Scenario 2: If RTRI is performed in parallel with the second test (T2), several outcomes are possible: Both T2 and RTRI are concordant with respect to HIV status (positive or negative). No additional testing is needed in this case. T2 is positive but RTRI is inconclusive/negative. Follow the flow chart 1. T2 is negative but RTRI is recent or LT. Follow the flow chart 2 shown below. This type of discrepant result may occur in small numbers, but it is important to investigate final status of these specimens to better understand performance of RTRI and if national algorithm is working well.Flow chart 2. Stepwise process to resolve T2 negative but RTRI recent or LT casesData Review and Analysis After completion of additional testing as per the flow charts, we will collect following numbers every month for further analysis starting with 2x3 table. A to F represent numbers in each category.Test 2 ResultPositiveNegativeTotalRTRI ResultsLong-termAEIRecentBFJInconclusive (i.e. Negative)CGKTotalDHLIn case of Scenario 1, comparison will be only with “Positive” column while Scenario 2 will include both “Positive” and “Negative” in the analysis.Scenario 1:% Agreement with national algorithm = (A+B) / D x 100.% Discordant rate = C/D x 100Scenario 2: % Agreement with national algorithm = [(A+B) + G] / L = 100% Discordant rate = [C+ (E+F)] / L x 100 For RTRI test to be acceptable as part of national algorithm in the future, discordant rate should be <1% or fraction thereof. This analysis will be conducted every month and in aggregate for all specimens tested for better statistical interpretation. Final outcome of “C” and “(E + F)” following Geenius testing is important to understand performance of RTRI and national testing algorithm in the context of final HIV status. Similar analysis will be conducted after Geenius testing. The scope of Geenius testing will be small because we expect few discordant results between RTRI and T2. In a retrospective analysis of >50,000 HIV-positive specimens tested with RTRI in several countries, about 0.2% (~100) were discordant. Since our intent is to compare antibody-based national testing algorithm with RTRI (another antibody-based assay), molecular testing (qualitative or quantitative PCR) does not represent a proper comparison and will not be used.Geenius HIV-1/2 Supplementary Assay (Bio-Rad):Geenius is a rapid confirmatory assay and is part of HIV testing algorithm in the U.S. and in PHIAs. It is a simplified version of the Western blot assay and incorporates multiple recombinant proteins or peptides for detection of antibodies to various HIV-1 and HIV-2 proteins. Its dual path platform format increases sensitivity of the test while allowing reasonable discrimination of HIV-1 and HIV-2. The test can be completed in 30 minutes and final results can be read and interpreted visually or with a reader. Geenius will be performed as per manufacturer recommended SOP. ILB has validated the test with DBS specimens. Therefore, DBS remains a viable option if liquid specimen is not available for further testing. Data will be reviewed and analyzed as described below after testing 10 or more discordant specimens with Geenius. This will likely require aggregate analysis of accumulated data.Geenius HIV-1/2 Results*HIV-1 PositiveNegativeTotalRTRI ResultsLong-termAEIRecentBFJInconclusive (i.e. Negative)CGKTotalDHL*HIV-2 positives, if any, should be excluded because RTRI can classify recency status of HIV-1 positive specimens only. For this analysis, dual infections can be counted as HIV-1 positive and indeterminate results should be classified as Geenius negative and counted appropriately. Data analysis:% Agreement with Geenius HIV-1/2 = (A+B+G) / L x 100.% Discordant rate with Geenius = (C+E+F)/L x 100Similar data analysis will be conducted comparing outcome of national testing algorithm with Geenius. Appendix F. Statement of Intent to Maintain Confidentiality I, …………………………………………, will at all times maintain the confidentiality of the patients whose patient data are reviewed as part of this project. At no time will I disclose the names of patients whose patient data are reviewed, or any information within their patient charts. All patient data will be reviewed in a private location. If there are questions related to the patient data, these will be discussed with the study team in a private location. Once the project is complete, individual-level patient data, including names and information, will not be discussed with anyone outside of the study team.Signed by:………………………………………………….Study Role:………………………………………………….Place:………………………………………………………Date:………………………………………………………Appendix G. Example analysis table shell to describe the percentage recent infection among persons with new HIV diagnosis by select variables* Total new HIV diagnosisRecent infection among new HIV diagnosisLong-term infection among new HIV diagnosisPersons who declined testing for recent infection*Select variablesN n n/N (%)nn/N (%)nn/N (%)Municipality12345SexMaleFemaleTransgenderAge category (years) 15-2425-3435-4445-5455-64>65Marital statusSingle (Never married)Married/Co-habitingSeparated/DivorcedWidowedPregnancy statusPregnantBreastfeedingNot pregnant/breastfeedingNot applicableRisk factors (if applicable)HeterosexualHomosexualInjection drug use (last 12 months)Blood transfusion (last 12 months)Work accidentGender-based violenceUnknown *Note: Where possible, conduct separate analysis for persons who did not receive testing for recent infection and persons who declined testing for recent infection. Appendix H. Community consultations around HIV recency testing A community engagement plan should include initial consultations to introduce recency testing as well as routine follow-up meetings. Concerns and considerations should be addressed prior to and during program implementation in order to secure community buy-in for recency testing and use of results. Initial consultations with community members should introduce the purpose of recency testing among newly diagnosed HIV-positive persons, advantages and potential effects of sharing results with clients tested, and information about the limitations on the accuracy of results from currently available rapid tests for recent infection. Initial consultations also provide an opportunity for community members to describe their perceived risks and benefits with HIV recency testing, provide vital information about their communities, propose considerations for program implementation, including how community can be involved in implementation, and determine jointly-led solutions to any concerns raised. Routine (e.g., quarterly or more frequent) community consultations should be used to remain engaged and identify new issues that may affect participation in HIV recency testing or any concerns of the downstream effects of consenting to this testing and use of results at the individual and/or population-level. This includes – and is not limited to – intimate partner violence; gender-based violence; mistrust of health care workers; legal barriers; decreased community appetite for index testing, self-testing, and other HIV testing modalities; and stigmatization of communities or subpopulations linked to recency clusters or a high proportion of recent HIV infection. The structure and scope of community consultations will be context-specific. In countries with vibrant and openly accepted HIV-infected and HIV-affected communities, consultations may include a mix of representatives from various community organizations, health facility members, health department officials, law enforcement, funders, religious leaders, among others. However, in countries with high stigma and discrimination and legal barriers, separate consultations with various community organizations may be needed to ensure the safety of their members. Examples of consultations include meetings with community advisory boards (group of community member representatives that serve as a liaison to country programs and facilitates trust and build a relationship between the community and country program), public forums in community centers, focus group discussions, and health fairs. Furthermore, community consultations must ensure that the community is involved in decisions on how data are collected, stored, analyzed, interpreted, and reported on or used. Country programs must ensure that all community members are safe throughout this process (e.g., limited distribution of recency hot-spots, brainstorming of interventions to stop chains of transmission, etc.)Best Practices for Community ConsultationsAll meetings should feature clearly defined goals and objectives from both the community and country office. All meeting discussions should be formally documented and these meeting summaries disseminated back to the community before or at future consultation meetings. Country programs should demonstrate plans have been made for pre- and post-test counseling for clients and referral to services for those who fear or experience repercussions from test results, as well as the implications of assisted partner notification services. Community consultation meetings should discuss the process of assisted partner notification (APN) and country programs should incorporate community feedback into APN procedures. Country programs should demonstrate that the community is engaged in discussions around the legal and social context of HIV recency testing among the various community groups. Country programs should have a “community action plan” that is in place to identify and respond to any challenges or social harms that that may arise during program implementation (testing, return of results, and/or data use) and advocate for appropriate changes. Country programs should consider including community representatives at sites of HIV recency testing to provide direct support to their community members. Finally, country programs should also consider working with communities and MoH to generate shareable media that could be used to advocate for and advertise the value of HIV recency testing and intended use of results to benefit the community.Consultations between communities and PEPFAR country programs should be routine ongoing activities, whose frequency is to be jointly determined by the communities and country programs themselves. For example in some contexts, quarterly meetings have been preferred. Through community score card activities in these contexts, partners have illustrated that quarterly meetings are frequent enough to see incremental change but not overly burdensome with regards to time commitment. Country programs should allow the community sufficient time to review and provide input to relevant HIV recency documents (e.g., information sheets, informed consent forms, data collection forms, SOPs, data analysis plans, and data use plans.) prior to and during program implementation. Similarly, country programs should provide routine updates to the community regarding the progress of recency testing and use of data. Plans and schedules for routine community monitoring and support should be outlined by country programs. Community monitoring is a system of community-developed and community-owned data collection and monitoring tools at the site of service delivery that leads to the implementation of solutions to respond to the evidence that communities have collected. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- s1 text brief overview of the statistical methodology
- ap statistics university of arizona
- hiv incidence defined as the rate of new hiv infections
- 1 alexfranko
- case study 1 supporting hiv education for health care
- subject disb
- sample sti standing delegation orders for nurse clinicians
- critical analysis of a report of a diagnostic or screening
Related searches
- measuring the rate of photosynthesis
- measure the rate of photosynthesis
- marketing is defined as quizlet
- opportunity cost is defined as quizlet
- profit is defined as quizlet
- the rate of teenage crime
- factors affecting the rate of photosynthesis
- what affects the rate of photosynthesis
- the benefits of new technology
- what is the rate of return
- how to find the rate of acceleration
- jesus as the son of man